Labcorp Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $14.3B+10.3% YoYTTM through 30 Jun 2026
Net Income $1B+34.4% YoYTTM through 30 Jun 2026
Free Cash Flow $1.2BTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 28.8% |
| EBITDA Margin | 15.3% |
| Operating Margin | 9.9% |
| Net Margin | 7.0% |
Returns
10.2%ROE
4.8%ROA
7.0%ROIC
Balance Sheet Health
Debt / Equity0.65x
Current Ratio1.80x
Net Debt$5.1B
Cash & Equivalents$141.8M
Quality Metrics
Altman Z-Score3.34
Piotroski F-Score8 / 9
FCF Margin8.1%
Rule of 4010.8
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $14B
Diluted EPS$12.09TTMFY2025: $10.46
Dividend
$1.44Per share, FY20260.46%Yield
Capital Allocation
Capex Intensity3.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Diagnostics Laboratories | $10.9B | +7.2% | |
| Biopharma Laboratory Services | $3.1B | +6.0% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.